Identification of thrombosis or bleeding risk in an individual with and without anti-platelet therapy

Abstract

The invention relates to a method for identification of an individual at increased risk of thrombosis or an atherothrombotic event, or a major bleeding event, comprising a step of assaying a biological sample from the individual for the presence of a SNP in the PPARGC1β, CNTN4, LZTS1 and KCNE4 genes, wherein the presence of a SNP in the PPARGC1β, CNTN4, LZTS1 and KCNE4 genes correlates with the individual being at increased risk of thrombosis or an atherothrombotic event, or a major bleeding event. Typically, the SNP is selected from the SNPs provided in Tables 1 and 2. The invention also provides a method of identifying an individual most likely to gain benefit from single anti-platelet therapy in the primary prevention of cardiovascular events, a method of identifying an individual most likely to gain benefit from dual anti-platelet therapy in the secondary prevention of cardiovascular events, and a method of identifying an individual likely to suffer a significant bleeding complication when undergoing treatment with drugs which influence haemostasis.

Dependencies are inferred from the claim text.